Larsson S, Svedmyr N
Ann Allergy. 1978 Dec;41(6):348-51.
SM 220, a new beta-receptor agonist, was compared with terbutaline by construction of dose response curves for FEV1, heart rate and blood pressure. The pharmacological profile of SM 220 after preclinical studies was that of a potent and highly selective bronchodilator. In this study the beta2 selectivity of SM 220 was poorer than that of terbutaline. The importance of commencing clinical evaluation of bronchodilators with a dose-response test is stressed.
新型β受体激动剂SM 220通过构建FEV1、心率和血压的剂量反应曲线与特布他林进行比较。临床前研究后SM 220的药理学特征显示其为一种强效且高选择性的支气管扩张剂。在本研究中，SM 220的β2选择性比特布他林差。强调了通过剂量反应试验开展支气管扩张剂临床评估的重要性。
